QTc Modeling and Simulation — Selected References
Journal Articles
Rohatagi S, Carrothers TJ, Wagg JK, Khariton T.
Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs. J Clin Pharmacol published September 4, 2009 as doi:10.1177/0091270009341184.
Presentations
Carrothers TJ, Khariton T, Rohatagi S. Performance Characteristics of Pooled Early Phase Concentration-QTc Modeling. [poster presentation]. Presented at: 37th Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 14-16, 2008; Philadelphia, Pennsylvania.
Walker JR, Rohatagi S, Salazar DE, Dmuchowski CF, Shenouda M, Swearingen D, R. Basavapathruni R, Cuddy T, Field J, Marier JF, Samata N, Izumi T, Sarapa N. Thorough QTC Study with Rivoglitazone Confirms No Exposure-QTC Response Predicted by PK/PD Modeling of Pooled Phase I/II ECG Data. [poster presentation]. Presented at: 37th Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 14-16, 2008; Philadelphia, Pennsylvania.
Rohatagi S, Song S, Khariton T, Carrothers TJ, Kuwabara-Wagg J, Kastrissios H. Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs. [poster presentation]. Presented at: American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson, Arizona.
Carrothers TJ. Concordance Between the Exposure-QTc Response Relationship in the Pooled Phase 1 Data vs. Thorough QTc Study. [invited presentation]. Presented at: 2nd Annual DIA Cardiac Safety Conference; December 3-4, 2007; Prague, Czech Republic. Reprinted courtesy of DIA, www.diahome.org.
Carrothers TJ. Modeling and Simulation of QTc Prolongation. [Pharsight webinar]. Presented on January 23, 2008.